» Articles » PMID: 16478725

Interrelated Roles for Mcl-1 and BIM in Regulation of TRAIL-mediated Mitochondrial Apoptosis

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2006 Feb 16
PMID 16478725
Citations 72
Authors
Affiliations
Soon will be listed here.
Abstract

The current study demonstrates a novel cross-talk mechanism between the TRAIL receptor death signaling pathway and the mitochondria. This newly identified pathway is regulated at the mitochondrial outer membrane by a complex between the prosurvival Bcl-2 member, Mcl-1 and the BH3-only protein, Bim. Under non-apoptotic conditions, Bim is sequestered by Mcl-1. Direct degradation of Mcl-1 by TRAIL-activated caspase-8 or caspase-3 produces Mcl-1-free Bim that mediates a Bax-dependent apoptotic cascade. Using Mcl-1 or Bim RNAi, we demonstrate that a loss in Mcl-1 expression significantly enhances the mitochondrial apoptotic response to TRAIL that is now mediated by freed Bim. Whereas overexpression of Mcl-1 contributes to the preservation of the mitochondrial membrane potential, Mcl-1 knockdown facilitates the Bim-mediated dissipation of this potential. Loss of Mcl-1 contributes to an increased level of caspase activity downstream of the mitochondrial response to TRAIL. Furthermore, the Mcl-1 expression level at the mitochondrial outer membrane determines the release efficiency for the apoptogenic proteins cytochrome c, Smac, and HtrA2 in response to Bim. These are the first findings to demonstrate the involvement of Bim in the TRAIL-mediated mitochondrial cascade. They also suggest that Mcl-1 may serve as a direct substrate for TRAIL-activated caspases implying the existence of a novel TRAIL/caspase-8/Mcl-1/Bim communication mechanism between the extrinsic and the intrinsic apoptotic pathways.

Citing Articles

An Azomethine Derivative, BCS3, Targets XIAP and cIAP1/2 to Arrest Breast Cancer Progression Through MDM2-p53 and Bcl-2-Caspase Signaling Modulation.

Acharya R, Deb P, Venugopala K, Pattanayak S Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770487 PMC: 11678930. DOI: 10.3390/ph17121645.


MDM2 drives resistance to Osimertinib by contextually disrupting FBW7-mediated destruction of MCL-1 protein in EGFR mutant NSCLC.

Liu J, Wei L, Miao Q, Zhan S, Chen P, Liu W J Exp Clin Cancer Res. 2024; 43(1):302.

PMID: 39543744 PMC: 11566350. DOI: 10.1186/s13046-024-03220-7.


Therapeutic effects of an innovative BS-HH-002 drug on pancreatic cancer cells via induction of complete MCL-1 degradation.

Wang A, Qiu R, Zhang D, Zhao X Transl Oncol. 2021; 15(1):101288.

PMID: 34847421 PMC: 8633684. DOI: 10.1016/j.tranon.2021.101288.


Lung cancer cells survive epidermal growth factor receptor tyrosine kinase inhibitor exposure through upregulation of cholesterol synthesis.

Howell M, Green R, Khalil R, Foran E, Quarni W, Nair R FASEB Bioadv. 2020; 2(2):90-105.

PMID: 32123859 PMC: 7003654. DOI: 10.1096/fba.2019-00081.


Mcl-1 signals pathway inhibitors in mouse peritoneal macrophage apoptosis infected with the Xinjiang strain of .

Wang X, Wang X, Zhang L, Zhang Y, Wang F, Lu Y Int J Clin Exp Pathol. 2020; 10(12):11952-11967.

PMID: 31966560 PMC: 6966066.